Pneumococcal vaccine recombinant - GlaxoSmithKline

Drug Profile

Pneumococcal vaccine recombinant - GlaxoSmithKline

Alternative Names: 2189242A; GSK 2189242A; S. pneumoniae adult vaccine - GlaxoSmithKline; Streptococcus pneumoniae recombinant-conjugated vaccine - GlaxoSmithKline

Latest Information Update: 02 Jan 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator GlaxoSmithKline
  • Class Pneumococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Otitis media; Pneumococcal infections

Most Recent Events

  • 26 Oct 2016 Efficacy and adverse events data from a phase II trial in Pneumococcal infections presented at the Infectious Disease Week-2016 (IDW-2016)
  • 01 Jul 2016 GlaxoSmithKline completes a phase II trial for Pneumococcal infections in USA (NCT01545375)
  • 22 Jun 2015 Phase-II development is ongoing in the US and Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top